Dr. Reddy's Laboratories (Dr. Reddy's (RDY)) just made a big move in the diabetes space. On Friday, the company launched its generic semaglutide injection in Canada, becoming one of the first to bring a cheaper version of the popular GLP-1 drug to the Canadian market. This comes shortly after Health Canada gave the green light on April 28, 2026.

Semaglutide is the active ingredient in Novo Nordisk's blockbuster drugs Ozempic and Wegovy, which have been in high demand for diabetes and weight loss. Dr. Reddy's generic version is specifically indicated for type 2 diabetes, and the company is positioning it as a more affordable option for patients. This is a big deal because GLP-1 drugs are expensive, and generic competition could help bring down costs.

Dr. Reddy's is no stranger to the generics game. It's one of the largest generic drug manufacturers globally, with a strong presence in North America (about half of its generics sales), India (20%), Russia (10%), and other regions. The company also has a solid injectables portfolio, which makes up 25% of its North American sales. This launch fits neatly into its strategy of expanding access to complex therapies like GLP-1s.

But while the news is positive for Dr. Reddy's, the broader market had a rough Friday. The Nasdaq was down 1.90%, and the S&P 500 fell 1.45%. So the stock is navigating a generally bearish environment, even as it makes strategic moves.

Technical Analysis

Let's look at the charts. Dr. Reddy's shares are currently trading at $13.64, which is 1.8% above the 20-day simple moving average (SMA) of $13.37. That's a short-term bullish signal. But the stock is 0.9% below the 100-day SMA of $13.74 and 2.3% below the 200-day SMA of $13.93. So there's some resistance at those longer-term levels.

The Relative Strength Index (RSI) sits at 53.44, which is neutral territory. That means the stock isn't overbought or oversold, and there's room for movement in either direction depending on what happens next.

Key Resistance: $14.50 — a level where the stock has stalled before.

Key Support: $13.50 — a level where buyers have stepped in previously.

Earnings & Analyst Outlook

Dr. Reddy's is scheduled to report its next financial results on July 22, 2026 (estimated). Here's what analysts are expecting:

• EPS Estimate: 17 cents (down from 20 cents)
• Revenue Estimate: $984.13 million (down from $997.00 million)
• Valuation: Forward P/E of 25.6x, which is a premium valuation

Analysts are cautious. The stock carries a consensus Hold rating with an average price target of $13.33, which is below the current price. Recent moves include:

• Goldman Sachs: Downgraded to Hold, target $13.00 (March 15)
• Morgan Stanley: Maintained Hold, target $13.50 (April 10)
• JP Morgan: Initiated at Neutral, target $13.25 (April 20)

MarketDash Edge Rankings

Here's how Dr. Reddy's scores on key metrics compared to the broader market:

• Value Rank: 80.57 — Strong value proposition relative to peers.
• Growth Rank: 75.05 — Solid growth potential.
• Quality Rank: 79.78 — Healthy balance sheet and operational efficiency.
• Momentum Rank: 19.62 — Weak momentum, suggesting the stock has been underperforming.

The Verdict: Dr. Reddy's has a mixed profile. It scores well on value, growth, and quality, but momentum is weak. That means the fundamentals look good, but the stock might struggle to move higher in the current market environment.

Price Action

Dr. Reddy's shares were up 0.22% at $13.64 on Friday, according to market data.

Photo by T. Schneider via Shutterstock